Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.95 Billion KRW | -37.21% |
| 2022 | 23.81 Billion KRW | 1.55% |
| 2021 | 23.45 Billion KRW | 31.93% |
| 2020 | 17.77 Billion KRW | 36.44% |
| 2019 | 13.03 Billion KRW | 10.4% |
| 2018 | 11.8 Billion KRW | 46.29% |
| 2017 | 8.06 Billion KRW | -21.02% |
| 2016 | 10.21 Billion KRW | 84.04% |
| 2015 | 5.55 Billion KRW | 44.27% |
| 2014 | 3.84 Billion KRW | -56.02% |
| 2013 | 8.74 Billion KRW | 558.75% |
| 2012 | 1.32 Billion KRW | 181.67% |
| 2011 | -1.62 Billion KRW | -194.17% |
| 2010 | 1.72 Billion KRW | -18.78% |
| 2009 | 2.12 Billion KRW | 2.08% |
| 2008 | 2.08 Billion KRW | -60.21% |
| 2007 | 5.23 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.22 Billion KRW | -38.16% |
| 2024 Q2 | 5.55 Billion KRW | 149.69% |
| 2023 Q4 | 3.59 Billion KRW | 1.65% |
| 2023 FY | 14.95 Billion KRW | -37.21% |
| 2023 Q1 | 3.89 Billion KRW | -4.64% |
| 2023 Q2 | 4.32 Billion KRW | 11.05% |
| 2023 Q3 | 3.53 Billion KRW | -18.2% |
| 2022 Q1 | 8.18 Billion KRW | 46.52% |
| 2022 Q2 | 5.47 Billion KRW | -33.13% |
| 2022 Q4 | 4.08 Billion KRW | -32.8% |
| 2022 Q3 | 6.07 Billion KRW | 11.02% |
| 2022 FY | 23.81 Billion KRW | 1.55% |
| 2021 Q1 | 5.55 Billion KRW | 41.76% |
| 2021 Q3 | 6.36 Billion KRW | 6.95% |
| 2021 Q4 | 5.58 Billion KRW | -12.18% |
| 2021 Q2 | 5.94 Billion KRW | 7.0% |
| 2021 FY | 23.45 Billion KRW | 31.93% |
| 2020 FY | 17.77 Billion KRW | 36.44% |
| 2020 Q3 | 3.96 Billion KRW | -38.14% |
| 2020 Q2 | 6.4 Billion KRW | 83.94% |
| 2020 Q4 | 3.92 Billion KRW | -1.09% |
| 2020 Q1 | 3.48 Billion KRW | -4.26% |
| 2019 Q4 | 3.63 Billion KRW | 56.72% |
| 2019 FY | 13.03 Billion KRW | 10.4% |
| 2019 Q1 | 3.42 Billion KRW | -20.72% |
| 2019 Q2 | 3.64 Billion KRW | 6.15% |
| 2019 Q3 | 2.32 Billion KRW | -36.21% |
| 2018 FY | 11.8 Billion KRW | 46.29% |
| 2018 Q3 | 2.68 Billion KRW | 5.28% |
| 2018 Q2 | 2.55 Billion KRW | 13.76% |
| 2018 Q1 | 2.24 Billion KRW | -20.93% |
| 2018 Q4 | 4.32 Billion KRW | 61.11% |
| 2017 FY | 8.06 Billion KRW | -21.02% |
| 2017 Q2 | 1.22 Billion KRW | -35.21% |
| 2017 Q4 | 2.83 Billion KRW | 34.63% |
| 2017 Q3 | 2.1 Billion KRW | 71.28% |
| 2017 Q1 | 1.89 Billion KRW | -27.5% |
| 2016 Q1 | 2.63 Billion KRW | 11.68% |
| 2016 Q3 | 2.76 Billion KRW | 26.47% |
| 2016 FY | 10.21 Billion KRW | 84.04% |
| 2016 Q2 | 2.19 Billion KRW | -17.01% |
| 2016 Q4 | 2.61 Billion KRW | -5.5% |
| 2015 Q2 | 1.52 Billion KRW | 115.39% |
| 2015 Q4 | 2.36 Billion KRW | 146.21% |
| 2015 FY | 5.55 Billion KRW | 44.27% |
| 2015 Q1 | 706.52 Million KRW | -49.41% |
| 2015 Q3 | 959.83 Million KRW | -36.93% |
| 2014 Q3 | 923.55 Million KRW | 579.65% |
| 2014 FY | 3.84 Billion KRW | -56.02% |
| 2014 Q4 | 1.39 Billion KRW | 51.22% |
| 2014 Q2 | 135.88 Million KRW | -88.65% |
| 2014 Q1 | 1.19 Billion KRW | 241.67% |
| 2013 Q2 | 1.78 Billion KRW | -35.87% |
| 2013 FY | 8.74 Billion KRW | 558.75% |
| 2013 Q4 | 350.31 Million KRW | -90.86% |
| 2013 Q3 | 3.83 Billion KRW | 114.99% |
| 2013 Q1 | 2.78 Billion KRW | 1221.95% |
| 2012 Q2 | 37.79 Million KRW | -95.76% |
| 2012 Q1 | 890.96 Million KRW | 0.0% |
| 2012 FY | 1.32 Billion KRW | 181.67% |
| 2012 Q4 | 210.39 Million KRW | 17.33% |
| 2012 Q3 | 179.31 Million KRW | 374.43% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | -1.62 Billion KRW | -194.17% |
| 2011 Q3 | 126.8 Million KRW | 164.1% |
| 2011 Q1 | 323.86 Million KRW | 260.14% |
| 2011 Q2 | -197.82 Million KRW | -161.08% |
| 2010 Q2 | 609.24 Million KRW | -19.06% |
| 2010 Q3 | 567.28 Million KRW | -6.89% |
| 2010 Q4 | -202.24 Million KRW | -135.65% |
| 2010 FY | 1.72 Billion KRW | -18.78% |
| 2010 Q1 | 752.71 Million KRW | -42.16% |
| 2009 Q1 | 528.91 Million KRW | -25.38% |
| 2009 Q2 | 1.32 Billion KRW | 150.38% |
| 2009 Q3 | -1.02 Billion KRW | -177.65% |
| 2009 Q4 | 1.3 Billion KRW | 226.55% |
| 2009 FY | 2.12 Billion KRW | 2.08% |
| 2008 Q1 | 1.25 Billion KRW | -21.18% |
| 2008 Q4 | 708.79 Million KRW | 310.13% |
| 2008 Q3 | -337.31 Million KRW | -174.49% |
| 2008 Q2 | 452.81 Million KRW | -64.03% |
| 2008 FY | 2.08 Billion KRW | -60.21% |
| 2007 Q3 | 630.69 Million KRW | -61.9% |
| 2007 Q1 | 1.35 Billion KRW | 0.0% |
| 2007 Q2 | 1.65 Billion KRW | 22.42% |
| 2007 FY | 5.23 Billion KRW | 0.0% |
| 2007 Q4 | 1.59 Billion KRW | 153.22% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ORIENT BIO Inc. | 9.58 Billion KRW | -56.037% |
| Green Cross Holdings Corporation | 603.58 Billion KRW | 97.522% |
| Green Cross Holdings Corporation | 458.68 Billion KRW | 96.74% |
| Green Cross Corporation | 458.68 Billion KRW | 96.74% |
| GeneOne Life Science, Inc. | -14.98 Billion KRW | 199.806% |
| Celltrion, Inc. | 1010.9 Billion KRW | 98.521% |
| Samsung Biologics Co.,Ltd. | 1802.76 Billion KRW | 99.17% |
| SK bioscience Co.,Ltd. | 142.24 Billion KRW | 89.486% |
| SK Biopharmaceuticals Co., Ltd. | 308.37 Billion KRW | 95.15% |
| Prestige BioPharma Limited | 689.07 Million KRW | -2070.328% |